03. Psoriasis

BOTTOM LINE

✔ Distribution of lesions can be very helpful in diagnosing psoriasis

✔ Screen for arthritis and cardiovascular disease in those with psoriasis

✔ Never treat with systemic steroids, as withdrawal can trigger life-threatening erythrodermic or pustular psoriatic flare

Background

  • Occurs in 1%-3% of the population. Transmitted genetically, with variable penetrance and disease manifestations due to environmental triggers
  • Precipitants:
    • Medications  (beta-blockers, antimalarials, lithium)
    • Systemic steroids, while effective at clearing psoriasis, can cause severe flares when withdrawn
    • Koebner’s phenomenon: Trauma may trigger lesions at sites of injury
    • URI’s (especially streptococcal) or cutaneous infections
    • Stress, alcohol
    • Systemic steroid withdrawal
  • Associated with diabetes, metabolic syndrome, arthritis, inflammatory bowel disease, malignancy (lymphoma and skin cancer), depression
  • Independent risk factor for cardiovascular morbidities, possibly in relation to inflammation 
  • Can be more emotionally than physically disabling, affecting patients’ self-image and leading to activity avoidance, some of which (e.g., sunbathing) could have a therapeutic benefit

Evaluation

  • Distribution:
    • Scalp, behind the ears, palms, and soles
    • Extensor extremities (knees and elbows)
    • Periumbilical and sacral areas
    • Gluteal cleft “gluteal pinking” = pathognomic for psoriasis
    • Nail changes (see below)
    • Usually spares palms, soles, and face
  • Morphology:
    • Well-demarcated pink papule or plaque with overlying adherent silvery scale
    • May have associated pustules
    • Can be confused with eczema or seborrheic dermatitis
    • Guttate psoriasis can resemble secondary syphilis or pityriasis rosea
  • Nail changes:
    • Pitting: Nail plate cells are shed much like the psoriatic skin scale, leaving punched out depressions. Not specific (can occur with eczema, fungal infections, alopecia)
    • Onycholysis: Separation of the nail from the nail bed, often simulating a fungal infection
    • Oil spots: Yellow-brown spots under the nail plate
  • Psoriatic arthritis:
    • 5-42% of psoriasis associated with seronegative spondyloarthropathy
    • The most common form is asymmetric oligoarthritis of small joints (hands, feet, wrists), but can also involve spine and entheses
    • Unlike rheumatoid arthritis, frequently involves the DIPs

 

Psoriasis variants and characteristics

  • Plaque psoriasis: Most common variant, erythematous plaques with well-defined margins and thick silvery scale in a classic distribution described above
  • Guttate psoriasis: Acute eruption of multiple small (<1cm) psoriatic lesions; primarily involves trunk in children/young adults; associated with a recent Strep infection. Tx: UV
  • Pustular psoriasis: May be life-threatening with widespread erythema/scaling and superficial pustules arising from suddenly formed erythematous areas in the flexural regions. Risk of hypocalcemia, high output heart failure, electrolyte abnormalities.  Tx: infliximab, cyclosporine, acitretin, derm consult
  • Inverse psoriasis: Involves intertriginous areas rather than extensor surfaces. Scale is typically absent. Can be confused for candida infection or tinea.
  • Erythrodermic psoriasis: Rare, generalized erythema/scaling at high risk for complications due to loss of skin barrier protection; warrants hospital admission for intensive topical steroid therapy and monitoring of fluid loss and high output cardiac failure.

Treatment

  • Treat until the skin feels normal (close eyes and run finger along plaque)
  • Topicals have variable efficacy and treatment dissatisfaction and nonadherence is high.
  • Psoriasis is not a scarring condition

Table 4: Treatment of Psoriasis

Modality

Comments

Emollients & keratolytics

Thick moisturizers (e.g., Vaseline, Eucerin®)

Keratolytics (e.g., tar, anthralin, salicylic acid 2-10% in petrolatum)

Topical steroids

See topical steroids table for potency ladder

Use lower potency on face or intertriginous skin to avoid side effects (e.g. atrophy, telangiectasia, or striae)

May need concomitant occlusive dressing at night to penetrate thick plaques.

Never give a systemic steroid to treat psoriasis as it can induce an erythrodermic pustular flare once the steroid is withdrawn

Vitamin D analogs

e.g., calcipotriene (Dovonex®) BID

Take longer than steroids to act but have a longer effect

Use on <40% of the body area and not more than 100 gm/wk to avoid toxicity

Can be used on the scalp and intertriginous areas (no side effects of steroids like atrophy)

Phototherapy

Narrowband or broadband UVB or PUVA (psoralen + UVA)

Can be used if topicals are not sufficient and the patient has too many morbidities for systemic immunosuppression

Other (use for >10% BSA)

Intralesional steroids (for few, small lesions), retinoids, MTX, cyclosporine, apremilast (PDE4 inhibitor), biologics (ex TNF inhibitors and IL12/23 inhibitors, many new agents in this category)

 

References

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.

Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899-912.          

Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013 May 1;87(9):626-33.

Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy - Chronic Pruritus. 6th Edition, Saunders. 2015: p215-217.